A detailed history of Boothbay Fund Management, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 612,277 shares of ABUS stock, worth $1.92 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
612,277
Previous 453,628 34.97%
Holding current value
$1.92 Million
Previous $1.13 Million 39.24%
% of portfolio
0.04%
Previous 0.04%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.26 - $2.92 $358,546 - $463,255
158,649 Added 34.97%
612,277 $1.58 Million
Q4 2023

Feb 14, 2024

SELL
$1.69 - $2.54 $64,377 - $96,756
-38,093 Reduced 7.75%
453,628 $1.13 Million
Q2 2023

Aug 14, 2023

SELL
$2.24 - $3.06 $296,275 - $404,733
-132,266 Reduced 21.2%
491,721 $1.13 Million
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $197,756 - $274,908
-88,680 Reduced 12.44%
623,987 $1.89 Million
Q4 2022

Feb 14, 2023

SELL
$1.91 - $2.85 $104,540 - $155,989
-54,733 Reduced 7.13%
712,667 $1.66 Million
Q3 2022

Nov 14, 2022

BUY
$1.88 - $2.88 $404,448 - $619,580
215,132 Added 38.95%
767,400 $1.47 Million
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $122,057 - $195,414
61,645 Added 12.56%
552,268 $1.5 Million
Q1 2022

May 16, 2022

BUY
$2.42 - $3.98 $77,394 - $127,284
31,981 Added 6.97%
490,623 $1.46 Million
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $928,776 - $1.38 Million
298,642 Added 186.65%
458,642 $1.78 Million
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $265,000 - $462,000
100,000 Added 166.67%
160,000 $686,000
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $41,955 - $58,904
16,782 Added 38.83%
60,000 $182,000
Q1 2021

May 17, 2021

SELL
$3.14 - $4.84 $12,754 - $19,660
-4,062 Reduced 8.59%
43,218 $144,000
Q4 2020

Feb 12, 2021

BUY
$2.76 - $4.97 $94,011 - $169,288
34,062 Added 257.69%
47,280 $168,000
Q3 2020

Nov 16, 2020

BUY
$1.75 - $6.2 $23,131 - $81,951
13,218 New
13,218 $41,000
Q1 2020

May 15, 2020

SELL
$1.01 - $3.42 $21,473 - $72,712
-21,261 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $18,497 - $61,444
21,261 New
21,261 $59,000
Q3 2018

Nov 14, 2018

SELL
$7.85 - $12.35 $376,800 - $592,800
-48,000 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$5.0 - $7.35 $240,000 - $352,800
48,000 New
48,000 $350,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $469M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.